TargetBeta
IL23R
interleukin 23 receptor · also IL-23R
2 programs in company-led studies act on IL23R, from 2 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule; the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| HS-20118 | Hansoh Pharmaceutical Group | phase 2 | 43 running | – | the company's pipeline |
| ABBV-859 | AbbVie | phase 1 | 11 running | – | the company's pipeline |
Conditions their studies are in
- Psoriasis, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 25, 2026HS-20118 · Hansoh Pharmaceutical Group · phase 2 · NCT07896915
- Feb 2027ABBV-859 · AbbVie · phase 1 · NCT07736638
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.